Newsroom

austin, texas – immunoprecise antibodies ltd. (nasdaq: ipa) today announced the launch of its ai-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. by combining advanced artificial intelligence with first-principles thinking, the biostrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency. traditional drug discovery often builds on outdated frameworks, layering new tools onto existing systems and perpetuating inefficiencies. ipa’s first-principles approach breaks from this mold by deconstructing challenges to their fundamentals and rebuilding processes from the ground up. this mindset led to the creation of lensai, ipa’s proprietary ai platform, which organizes vast biological datasets into a unified framework, eliminating silos and accelerating discoveries. the ipa pipeline introduces a new era of ai-enhanced therapies designed to meet modern medical demands while addressing critical unmet needs. by pairing cutting-edge computational insights with rigorous lab validation, ipa ensures the delivery of treatments that are not only groundbreaking but also highly effective and reliable. powered by lensai's in silico workflows, the pipeline integrates data with precision at every stage of development, enabling therapies that are faster, more targeted, and impactful for the future of medicine. "our ai-powered pipeline represents a major leap forward for ipa," said dr. jennifer bath, ceo of immunoprecise antibodies. "by harnessing ai and rethinking drug discovery from the ground up, we are not just improving the process—we are fundamentally changing what’s possible. this pipeline lays the foundation for groundbreaking advancements in therapeutic development, embodying our vision of innovation driven by clarity, precision, and purpose." this launch marks a pivotal moment for ipa as it continues to set new standards in biotherapeutics. by tackling complex therapeutic challenges and addressing some of the world’s most pressing medical needs, ipa is poised to lead the next wave of ai-powered drug discovery. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact investors@ipatherapeutics.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits and impact of the ai-driven pipeline, the potential for ai-enhanced therapeutic assets to accelerate drug discovery, and the company’s ability to develop and commercialize new therapeutic candidates. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including risks related to scientific and technological developments, regulatory approvals, industry competition, and broader market conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

-biostrand now offers a customizable application programming interface (api) with its new software offering, lensai api, featuring the ability to integrate sizable databases and electronic health records with large language models. -biostrand’s novel software is rapidly and directly integrable into pharmaceutical, healthcare, and technology companies to enhance drug discovery capabilities. -this proprietary software provides the integration of electronic health records, enhancing ai-driven drug discovery and development for industry professionals. victoria, british columbia, june 10, 2024 - immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, today announces the commercial release of lensai api, hereafter referred to as the ‘software’, by its subsidiary, biostrand. this advanced ai-driven software solution is available immediately. more details on this new offering will be unveiled today at 2:00 pm et, with an additional presentation, live demonstration, and interview at 6:30 pm et, all taking place at the intersystems global summit 2024. this premier event, which attracts over 1,200 industry leaders from more than 28 countries, showcases the latest innovations in the field. ipa, the #1 ranked contract research organization by roots analysis2, serves 19 of the top 20 global pharmaceutical companies and over 600 clients in the pharmaceutical and biotech industries. leveraging feedback from these long-term relationships, the development of this ai-driven software is in direct response to meeting ongoing industry pain points and needs. these new software capabilities demonstrate innovation by combining biostrand’s patented lensai technology with electronic health records through a customizable interface to enable unprecedented research and drug discovery capabilities. dr. dirk van hyfte is leading the launch of this exciting integration, enabling industry professionals to quickly and easily access and merge patient data, company research data, and extensive life science databases. through this new release, corporations will be able to analyze major datasets related to generating novel and potentially safer and more effective drugs, as the biostrand team continues to develop a full lensai data management platform, expected to be released in q1/q2 2025. dr. dirk van hyfte stated, "we have received significant interest in our new technology from large healthcare, pharmaceutical, and technology companies. they are keen on accessing our unique capabilities through an integration that enables them to benefit directly from biostrand's novel applications for data analysis and cutting-edge drug discovery. the company regards the commercial launch of this pioneering software as its most significant ai breakthrough to date, poised to significantly enhance global drug discovery and development processes. by integrating biostrand’s software with electronic health records, and adding biostrand’s application programming interface, we have surpassed internal timelines and milestones, supporting the rapid commercialization of these high-demand capabilities." these new commercial capabilities will significantly enhance biostrand’s ability to commercialize: partnerships with large companies: major pharmaceutical, technology, and healthcare companies will be able to rapidly leverage biostrand’s new software capabilities through partnerships that may include upfront payments, clinical milestones and commercial royalties. subscription model: biostrand is offering a subscription service that enables a wide range of technology, healthcare, and pharmaceutical companies to access biostrand’s unique capabilities using integration of the software into their existing platforms, with a strong probability of enhancing their drug discovery and development programs. in light of the upcoming presentation at the intersystem’s global summit 2024, dr. dirk van hyfte has requested that the live podcast, media events, and interviews be recorded and made available to the public whenever possible. we also encourage everyone who can attend the live demonstration at the summit to join and support this exciting public commercial launch. you can register: intersystems global summit 2024 registration. investor contact: investors@ipatherapeutics.com 1www.strategyand.pwc.com/de/en/industries/pharma-life-science/re-inventing-pharma-with-artificial-intelligence.html 2roots 2022, antibody discovery services and platforms market (4th edition), 2021-2035; pp.118 about immunoprecise antibodies ltd. the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, risks that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments with higher efficacy and lower side effects will not be achieved, risks that the benefits to drug discovery, protein-based therapeutics, and synthetic biology won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

dirk van hyfte md, phd, co-founder and head of innovation of biostrand, to present findings live next week at the himss24 conference in orlando, florida victoria, british columbia (canada), march 7, 2024 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, today announced the development of a foundation ai model that represents a significant advancement in life sciences research and development. the company’s model uniquely combines the strengths of large language models (llms) through an advanced stacking technique with biostrand's patented hyft® technology. the hyft's ability to pinpoint unique 'fingerprints' in biological sequences enables the stacked llms to apply their vast knowledge base with greater specificity, leading to more accurate predictions and insights. this integration marks a pivotal moment in the utilization of artificial intelligence for complex biological data analysis and drug discovery. unveiling the intricacies of hyft technology central to the success of biostrand's foundation ai model is its utilization of its patented hyft technology, a sophisticated framework designed to identify and leverage universal fingerprint™ patterns across the biosphere. these fingerprints act as critical anchor points, encompassing detailed information layers that bridge sequence data to structural data, functional information, bibliographic insights, and beyond, serving as the great connector between disparate realms of knowledge. biostrand’s platform core is built upon a comprehensive and continuously expanding knowledge graph, mapping 25 billion relationships across 660 million data objects, and linking sequence, structural, and functional data from the entire biosphere to written text such as scientific literature, providing a holistic understanding of the relationships between genes, proteins, and biological pathways. the seamless integration of hyfts with stacked llms enables the biostrand ai model to decode the complex language of proteins, unlocking insights crucial for antibody drug development and precision medicine. large language models (llm), originally developed for natural language processing (nlp), can also be applied on “the language of proteins” enabling insights into tasks including, but not limited to, protein structure prediction, antibody binding optimization, and protein mutagenesis. to understand ‘the language of proteins’, it is essential to detect meaningful words and word boundaries. this is where the hyfts serve as critical enablers. by harnessing hyft's sophisticated computational capabilities, the previously abstract notion of identifying functional units or "words" in protein sequences is made tangible, allowing for precise mapping and analysis. the advanced foundation ai model employs a distinctive approach known as "llm stacking" to intelligently combine different llms, with the hyfts linked to specific features found in various llms. using a natural language analogy, this would mean one is able to distinguish the meaning of ‘apple’ based specifically on the context of the word, in other words, is the word “apple” referring to a type of fruit versus ‘apple’, silicon valley pioneer. in a life sciences context, these features, for example, could include identification of critical amino acid residues involved in protein binding or detecting sequence variations associated with disease susceptibility. the sequence diversity harnessed by the hyfts was discovered during the clustering of next generation sequencing data sourced from ipa’s pipeline subsidiary, talem therapeutics, utilizing the hyft network combined with llm stacking. through the incorporation of various features provided by llm stacking in this study, it was possible to differentiate between binding and non-binding antibodies, even when they shared similar hyft patterns. pioneering a new frontier in life sciences the concept of "word boundaries" within protein languages offers a groundbreaking approach to unlocking the complexities of protein structure and function, filling a void in the knowledge base of researchers and drug developers alike. by enabling precise identification and manipulation of functional units within proteins, this innovative methodology paves the way for advancements in drug discovery, protein-based therapeutics, and synthetic biology. it promises not only to accelerate the development of targeted treatments with higher efficacy and lower side effects but also to revolutionize protein engineering and design. this approach, leveraging cutting-edge computational models and analysis techniques, stands to significantly reduce research and development timelines and costs . advancing drug discovery and precision medicine - lensai ™ integrated intelligence technology™ this methodology revolutionizes biotechnology and pharmaceutical research by providing a robust framework for drug discovery, protein engineering, and the development of protein-based therapeutics. the hyft technology’s application of "word boundaries" is particularly compelling, as it aims to significantly accelerate research and development processes. through the facilitation of targeted treatments and the innovation of novel therapies, the hyft technology offers a reduction in development timelines and costs . by providing a comprehensive understanding of the complex relationships between genes, proteins, and biological pathways, the model paves the way for the development of targeted therapies and personalized treatment strategies. reaffirming biostrand's leadership in biotech innovation "the development of our foundation ai model, powered by our unique 'llm stacking' approach and patented hyft technology, marks a significant milestone in the field of biotechnological research," stated dirk van hyfte md, phd, co-founder and head of innovation of biostrand. "this innovation not only expands the boundaries of current biotech research, but also establishes a new standard for the application of ai in solving complex biological challenges." “as the global community recognizes the transformative potential of artificial intelligence in the life sciences,” dr. hyfte continued, “i am confident that biostrand's foundation ai model will stand at the forefront of innovation and the future of ai-driven solutions in biology and drug discovery.” a future of collaborative discovery in alignment with our mission to foster collaboration and innovation within the life sciences community, we are excited to announce that ipa's ceo, dr. jennifer bath, will participate in the h.c. wainwright 1st annual artificial intelligence based drug discovery & development virtual conference today march 7th, 2024. this participation underscores our commitment to leading the conversation on the future of ai-driven solutions in biology and medicine. additionally, we are thrilled to announce the participation of dirk van hyfte md, phd, co-founder and head of innovation of biostrand, alongside our esteemed technology partner, intersystems, at this year's himss24 conference in orlando, florida. together, we will be showcasing our latest advancements in the field of healthcare technology through intersystems’s innovator introduction program. our presentation will focus on introducing our groundbreaking universal foundation ai model for multiscale biological data integration. we invite you to join us for our lightning pitch session, where we will delve into the capabilities and potential impact of our universal foundation ai model. also, we welcome you to engage in fruitful conversations at intersystem's booth, #1361 at the himss conference, march 12th-14th, 2024. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, risks that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments with higher efficacy and lower side effects will not be achieved, risks that the benefits to drug discovery, protein-based therapeutics, and synthetic biology won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

victoria, british columbia, november 27, 2023 - immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, is pleased to announce important board of director changes and upcoming financial reporting activities. new board chairman mitch levine joined the board of directors of ipa at ipa’s recent annual general meeting and has been appointed as chairman of the board, bringing a wealth of experience from the life sciences industry and financial strategy, particularly in nasdaq market operations. as ceo and chairman of smarthealth dx since 2022, levine has focused the company’s strategy, operational efficiency, and boosted corporate value. at oncocyte, he drove significant growth as cfo from 2017 to 2022, overseeing all financial operations of the company, managing capital raises, navigating nasdaq complexities, and leading major acquisitions and a key licensing deal in china. his capital markets expertise was widely recognized as founder and managing member of enable capital management, llc, where for 17 years they provided growth capital to small- and mid-sized public companies, many traded on nasdaq. his background also includes a foundational role at the shemano group, a san francisco-based investment bank focused on technology and life sciences sectors. dr. jennifer bath, ceo of immunoprecise antibodies, lauds levine’s combination of life sciences and financial acumen as invaluable for ipa. his guidance is expected to be crucial for ipa's innovative growth, particularly in antibody discovery and development, and to further establish ipa as a leader in the biotech industry. “we anticipate his guidance in financial strategies and market dynamics to be a significant asset in driving ipa's innovative growth and expansion, especially as we progress our cutting-edge biotechnologies like hyft® and lensai™.” remuneration and nomination committee chairman chris buyse is currently the chairman of the remuneration and nomination committee, effective october 2, 2023. mr. buyse brings both experience with nasdaq traded life science companies as well as pharmaceutical industry experience. he is currently a board member and chairman of the audit committee of inventiva sa, a dual-listed company on euronext paris and nasdaq, and a board member and member of the audit committee of hyloris pharmaceuticals, a company listed on euronext brussels. new audit committee chairman additionally, ipa is pleased to announce the appointment of dirk witters as the new chairman of the audit committee, effective november 15, 2023. mr. witters brings a strong background in finance and auditing, having previously served as executive partner in a corporate finance boutique and was advisor to the founder of new rhein healthcare investors, a private equity investment firm focused on healthcare therapeutics and medical devices, where he assisted with the capital raise of the second investment fund. mr. witters also spent 20+ years with kbc group’s corporate and investment banking division where he gained experience in business development, strategy execution, advisory and corporate finance. the appointment of mr. witters as chairman of ipa’s audit committee underscores ipa's commitment to maintaining the highest standards of financial oversight and corporate governance. "we at ipa are thrilled to embark on this exciting new chapter with the support of our shareholders and stakeholders, guided by our esteemed leadership team. the appointment of mitch levine as our chairman, along with chris buyse as chairman of the remuneration and nomination committee, and dirk witters as the new chairman of the audit committee, marks a significant milestone for our company, stated dr. bath.” their combined expertise in the life sciences sector, financial strategy, and corporate governance, especially in nasdaq-listed environments, not only reflects the strong backing we have from our shareholders but also reinforces our commitment to excellence and innovation in biotechnology. we believe that their leadership and insights will be instrumental in steering ipa towards groundbreaking advancements and sustained growth in the industry." upcoming second quarter 2023 earnings release call ipa will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2024, on thursday, december 14, 2023, at 10:30 am eastern time. the financial results will be issued in a press release prior to the call. investors, analysts, and other stakeholders are invited to participate in the conference call, during which ipa's senior leadership will discuss the financial results and provide insights into the company's performance and future outlook. title: ipa reports financial results and recent business highlights for second quarter fiscal year 2024 event date: december 14, 2023 event time: 10:30 et webcast url: https://events.q4inc.com/attendee/905281713 participant details participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 conference id: 9236374 about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com source: immunoprecise antibodies ltd. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the future expectations for ipa, including expectations regarding ipa achieving groundbreaking advancements and sustained growth in the industry. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

victoria, british columbia, june 13, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, is excited to announce a new use case for the information integration dilemma (iid) solution developed by its subsidiary, biostrand®. link to use case here the iid has long been a significant challenge in the biotechnology industry, with researchers and investors grappling with the complexities of integrating diverse data types to gain meaningful insights. biostrand's lensaitm platform and patented hyft® technology have successfully addressed this issue, providing a unified framework that encapsulates and integrates diverse data modalities, including syntactical (sequence) data, 3d structural data, unstructured scientific information, and more. this breakthrough approach has paved the way for quicker and more potent biological discoveries, and the unveiling of this use case demonstrates the practical application of this technology in the field of biotechnology. this use case provides a detailed look at how hyft technology and the lensai platform can be utilized to solve complex biological problems, offering a glimpse into the future of biotherapeutic research and development. "our newest use case stands as a potent testament to how we've successfully navigated the iid. it demonstrates the power of integrating and organizing heterogeneous data types and reflects depth of insights gleamed using our comprehensive knowledge graph. this graph, teeming with over 25 billion relations, bridges the gap between sequence, structure, and textual data in a manner that was previously inconceivable. the application of these interconnections has unearthed insights and relationships that were otherwise invisible, enhancing our understanding of biological systems.” the unveiling of this use case is a testament to immunoprecise's commitment to innovation and its dedication to solving complex problems in the field of biotechnology. the company continues to lead the way in ai-driven biotherapeutic research and technology, and this latest development further solidifies its position as a pioneer in the industry. about biostrand’s hyft technology biostrand's hyft technology extracts unique patterns, known as universal fingerprint™ patterns, from the entire biosphere, and integrates them with various data sources, such as scientific papers and medical records. the resulting knowledge graph encompasses over 660 million hyfts and more than 25 billion relations, providing a powerful resource for researchers and ai-driven analysis. the lensai platform, powered by hyft technology, takes advantage of the latest advancements in large language models (llms) to bridge the gap between syntax (sequences) and semantics (functions). this enables the platform to extract valuable insights from vast amounts of data, without the limitations of traditional llms. ipa's support of biostrand's pioneering work reinforces its commitment to investing in cutting-edge biotechnology solutions with the potential to transform the industry. about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the drug development process of the integration of ipa’s lensai in silico humanization platform with its hyft technology, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

victoria, british columbia, june 6, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”) today introduced a transformative ai-driven rapid therapeutic screening platform, the result of a collaboration between ipa canada and its subsidiary, biostrand®. this innovative solution aims to significantly expedite the early stages of drug discovery by enabling the early elimination of less promising therapeutic candidates, thereby reducing time, cost, and the risk of failure during later stage discovery. the current transgenic animal model market, reaching usd 17.7 billion in 2021 and expected to grow by 8.1% cagr from 2022 to 2028¹, has been widely adopted in novel therapeutic discovery, primarily to avoid what was previously seen as time-consuming, expensive, risk-laden, and sometimes unsuccessful humanization processes. however, despite its widespread adoption, transgenics pose limitations of their own, such as a lack of diversity in therapeutic outputs, loss of therapeutic efficacy, and high costs. addressing these challenges, biostrand's recently patented technology introduces a reliable, scalable, and cost-effective alternative for early-stage therapeutic discovery. biostrand’s platform, termed the hyft® proprietary proteome presence assessment, optimizes potential therapeutic drug candidates at an early stage using the multi-functional lensai™ in silico humanization platform integrated with its patented hyft technology. this allows a multitude of potential therapies to be analyzed concurrently, reducing analysis time and costs, and ensuring that only the most promising candidates proceed further into the drug discovery process. (left) traditional antibody discovery and development timeline. linear model imposes increased risk of attrition due to the cost of lead candidate advancement with minimal insight into future clinical viability. (right) the new enhanced predictive insights gained by ipa’s new in silico-driven discovery cycle, which increases the probability of clinical success, saving our partners time and money. the concept of in silico humanization refers to the computational process of making an antibody or protein from a non-human source resemble human proteins. this is crucial for reducing the likelihood of immune responses against therapeutics, while preserving their functionality. biostrand's patented hyft technology, incorporated into their proprietary lensai software, screens the entire human proteome (the entire complement of proteins that is or can be expressed by a cell, tissue, or organism), as well as various animal proteomes, against candidate therapeutics. this screening is accomplished in under one minute per candidate molecule. this process advances the most 'human-like' molecules, speeding up humanization, reducing the manipulation required before use in clinical trials, and offering a rapid, scalable, and cost-effective alternative to transgenic animal models. other existing methods can only assess candidates against a subset of the human proteome, which can result in an incomplete evaluation of a protein's humanness and immunogenicity. hyft technology, however, uniquely addresses this limitation with several distinct advantages, including: use of the most comprehensive human proteome reference set, enabling more thorough comparisons. the ability to extract unique universal fingerprint™ patterns from biological sequences. the capacity to compare the humanized therapeutics to the human proteome, evaluating its similarity to endogenous proteins. the ability to capture both sequence and structural information, enabling a better understanding of the protein's function. scalability and high-throughput capabilities, allowing for rapid assessments of numerous candidate proteins against extensive reference datasets. leveraging these unique capabilities, the hyft proprietary proteome presence assessment offers a more accurate and complete assessment of candidates' humanness and immunogenicity. this supports the development of safer, more effective therapeutic proteins and antibodies while greatly streamlining the drug development process. "ipa's smooth fusion of computer-driven humanization and immunogenicity testing paves the way for faster development and boosts the potential of new treatment methods," stated dr. ingrid brands, co-founder and general manager of biostrand. "our dedication to innovation and pushing the limits of ai-driven therapeutic discovery is represented in this collaboration and integration. we're all about setting new standards in medicine and driving value for our investors.” ipa has provided insights into its strategic approach for monetizing this breakthrough technology. the plan involves targeting their extensive existing client base, which includes 19 of the top 20 pharmaceutical companies and hundreds of biotechnology firms. these clients typically face substantial costs, when using transgenic animals, to progress a single therapeutic candidate through the commercialization process. these costs often reach tens to hundreds of millions of dollars per molecule, encompassing upfront payments, milestone payments, and commercial royalties. by introducing a more reliable, efficient, and cost-effective solution via ipa's ai-driven platform, the company is well-positioned to provide greater results and value for its clients, reducing their costs and accelerating their drug discovery timelines. this increase in quality, productivity, and value is expected to translate directly into increased revenue streams for ipa, fostering substantial financial growth for the company and its investors. ¹ https://www.gminsights.com/industry-analysis/animal-model-market about biostrand’s hyft technology biostrand's hyft technology extracts unique patterns, known as universal fingerprint™ patterns, from the entire biosphere, and integrates them with various data sources, such as scientific papers and medical records. the resulting knowledge graph encompasses over 660 million hyfts and more than 25 billion relations, providing a powerful resource for researchers and ai-driven analysis. the lensai platform, powered by hyft technology, takes advantage of the latest advancements in large language models (llms) to bridge the gap between syntax (sequences) and semantics (functions). this enables the platform to extract valuable insights from vast amounts of data, without the limitations of traditional llms. ipa's support of biostrand's pioneering work reinforces its commitment to investing in cutting-edge biotechnology solutions with the potential to transform the industry. about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the drug development process of the integration of ipa’s lensai in silico humanization platform with its hyft technology, and statements relating to ipa’s expected increased revenue streams and financial growth . in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai in silico humanization platform with its hyft technology may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

victoria, british columbia may 30, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), an ai-driven biotherapeutic research and technology company, today announced that its subsidiary, biostrand®, has successfully solved the information integration dilemma (iid) by developing a unique technology design that enables their patented hyft technology to encapsulate and unify diverse data modalities - including syntactical (sequence) data, 3d structural data, unstructured scientific information (e.g. scientific literature), and beyond - into a singular, integrated framework. this breakthrough approach facilitates efficient data fusion, enabling a comprehensive analysis and interpretation of complex biological data. with hyfts, biostrand effectively addresses the iid, paving the way for quicker and more potent biological discoveries. this innovation has the potential to bring a paradigm shift in various domains including drug development, biomarker discovery, and the study of disease pathology, among others. the iid has long been a significant challenge for the biotechnology industry, as researchers and investors have grappled with the complexities of integrating various data types to gain meaningful insights. in the rapidly evolving field of biotechnology, data is generated from multiple sources such as scientific literature, experimental data, and genomic information. the integration of these different data types is critical for accelerating innovation and driving the discovery of novel therapeutics. however, traditional approaches have struggled to efficiently combine and analyze this diverse data, often leading to incomplete or inaccurate conclusions. biostrand's breakthrough approach leverages its patented hyft® technology and lensaitm platform, which together enable the efficient analysis and understanding of complex biological data. by solving the iid, biostrand has unlocked new possibilities for the discovery and development of novel therapeutics, which is expected to benefit both patients and the investor community. dirk van hyfte, co-founder and head of innovation of biostrand, said, "we are thrilled to have overcome the information integration dilemma, which has long been a major hurdle in our industry. our hyft technology and lensai platform are now poised to revolutionize the way researchers and ai-driven systems process and analyze complex biological data, ultimately leading to faster and more effective drug discovery and development." biostrand's hyft technology extracts unique patterns, known as universal fingerprint™ patterns, from the entire biosphere, and integrates them with various data sources, such as scientific papers and medical records. the resulting knowledge graph encompasses over 660 million hyfts and more than 25 billion relations, providing a powerful resource for researchers and ai-driven analysis. the lensai platform, powered by hyft technology, takes advantage of the latest advancements in large language models (llms) to bridge the gap between syntax (sequences) and semantics (functions). this enables the platform to extract valuable insights from vast amounts of data, without the limitations of traditional llms. ipa's support of biostrand's pioneering work reinforces its commitment to investing in cutting-edge biotechnology solutions with the potential to transform the industry. the successful resolution of the information integration dilemma not only demonstrates the innovative nature of biostrand's technology but also highlights the company's dedication to improving the lives of patients worldwide. about immunoprecise antibodies ltd: immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of in silico models and wet-lab experiments may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies